Fast-growing biotech startup targets 2020 for Series A funding, start of clinical trials


The St. Louis-based startup, Wugen, is developing “off the shelf” medicine to treat various cancers. The company was created from technology licensed from Washington University researchers.

Previous Major Houston hospital system plans $250M Woodlands campus expansion
Next Denver’s South Broadway is going through big changes. Again.